Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 11/20 | 0.65 |
| ▸ | MAPT | P10636 | 7/20 | 0.65 |
| ▸ | GAA | P10253 | 6/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | SNCA | P37840 | 4/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | BCHE | P06276 | 2/20 | 0.65 |
| ▸ | ACHE | P22303 | 2/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
| ▸ | MAOA | P21397 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | CNR1 | P21554 | 1/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8941074 | 0.90 | MAOA (0.55) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL2720811 | 0.89 | NOX1 (0.65) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL7768973 | 0.88 | NOX1 (0.77) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL29499615 | 0.86 | MAOA (0.49) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL27581232 | 0.86 | MAOA (0.49) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL27756460 | 0.86 | NOX1 (0.74) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL22584033 | 0.82 | NOX1 (0.74) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL9114 | 0.81 | NOX1 (1.00) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL2504207 | 0.81 | NOX1 (1.00) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL6315328 | 0.81 | NOX1 (1.00) | NOX1MAPTGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118324975-A | Phenothiazine skeleton macromolecule cationic photoinitiator and preparation method and application thereof | 江南大学 | 2024-07-12 | — | — | CN | claimed |
| CN-118324975-A | Phenothiazine skeleton macromolecule cationic photoinitiator and preparation method and application thereof | 江南大学 | 2024-07-12 | — | — | CN | disclosed |
| EP-3488868-B1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION CONTAINING SULFASALAZINE AND / OR A SULFASALAZINE ORGANIC SALT, PRODUCTION PROCESS AND USE | MEDAC GES FUER KLINISCHE SPEZIALPRAEPARATE MBH (DE) | 2023-09-13 | — | — | EP | disclosed |
| US-11690857-B2 | Pharmaceutical composition for oral administration containing sulfasalazine and/or a sulfasalazine organic salt, production process and use | MEDAC GESELLSCHAFT FUER KLINISCHE SPEZIALPRAEPARATE MBH | 2023-07-04 | — | — | US | disclosed |
| US-20210369743-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION CONTAINING SULFASALAZINE AND/OR A SULFASALAZINE ORGANINC SALT, PRODUCTION PROCESS AND USE | MEDAC GESELLSCHAFT FUER KLINISCHE SPEZIALPRAEPARATE MBH (DE) | 2021-12-02 | — | — | US | disclosed |
| CN-109467561-B | Double-donor hole transport material containing phenothiazine structure, preparation method thereof and perovskite solar cell | 广东工业大学 | 2021-07-02 | — | — | CN | disclosed |
| EP-3713605-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION CONTAINING SULFASALAZINE AND / OR A SULFASALAZINE ORGANIC SALT, PRODUCTION PROCESS AND USE | medac Gesellschaft für klinische Spezialpräparate mbH (DE) | 2020-09-30 | — | — | EP | disclosed |
| EP-3713918-A1 | SULFASALAZINE SALTS, PRODUCTION PROCESSES AND USES | medac Gesellschaft für klinische Spezialpräparate mbH (DE) | 2020-09-30 | — | — | EP | disclosed |
| EP-3630188-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF METHOTREXATE AND NOVOBIOCIN, AND THE USE OF SAID COMPOSITION IN THERAPY | Truly Translational Sweden AB (SE) | 2020-04-08 | — | — | EP | disclosed |
| EP-2751104-B1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-09-25 | — | — | EP | disclosed |
| WO-2004087659-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004085423-A1 | PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CHEMOKINE OR H1 MEDIATED DISEASE STATE | ASTRAZENECA AB (SE) | 2004-10-07 | — | — | WO | disclosed |
| US-5155148-A | For stabilizing oxidizable rubbers, oils; co-polymerizable through unsaturated site | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
| EP-0420790-A1 | Ester derivatives from p-hydroxydiphenylamine | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 1991-04-03 | — | — | EP | disclosed |
| EP-0106937-B1 | PHENOTHIAZINE LEUCODYES FOR ELECTROCHROMIC RECORDING | International Business Machines Corporation (US) | 1987-09-23 | — | — | EP | disclosed |
| EP-0062257-B1 | SULPHUR DYES, PROCESS FOR THEIR PREPARATION AND THEIR USE | CASSELLA Aktiengesellschaft (DE) | 1984-07-25 | — | — | EP | disclosed |
| EP-0106937-A2 | Phenothiazine leucodyes for electrochromic recording | International Business Machines Corporation (US) | 1984-05-02 | — | — | EP | disclosed |
| US-4439280-A | Phenothiazine leucodyes for electrochromic recording | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 1984-03-27 | — | — | US | disclosed |
| US-4403995-A | Sulphur dyestuffs, a process for their manufacture and their use from hydroxy-diphenylamine compounds | CASSELLA AKTIENGESELLSCHAFT (DE) | 1983-09-13 | — | — | US | disclosed |
| EP-0062257-A1 | Sulphur dyes, process for their preparation and their use | CASSELLA Aktiengesellschaft (DE) | 1982-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369743-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION CONTAINING SULFASALAZINE AND/OR A SULFASALAZINE ORGANINC SALT, PRODUCTION PROCESS AND USE | SI, ALPI, SOST | NOX1 614/4885MAPT 3679/4885GAA 1285/4885 |
| US-11690857-B2 | Pharmaceutical composition for oral administration containing sulfasalazine and/or a sulfasalazine organic salt, production process and use | SI, SOST, ALPI | NOX1 849/4885MAPT 3526/4885GAA 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.